DBV Technologies S.A.
DBVT Healthcare Biotechnology
DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 53.3%, EPS grew 61.3% and free cash flow fell 56.2%, each against the same quarter a year earlier.
Follow DBVT
DBV Technologies S.A. (DBVT) EV/Sales
As of 16 October 2026, DBV Technologies S.A. (DBVT) trades at a EV/Sales of 124×. Over the past ten years it has ranged from −43.1× (December 2021) to 291× (April 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 60.5× | 808.15% |
| FY2024 | 6.7× | — |
| FY2023 | −6.7× | — |
| FY2022 | −33.6× | — |
| FY2021 | −7.4× | — |
| FY2020 | −12.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 253× | (7.11%) |
| Mar 2026 | 272× | 349.49% |
| Dec 2025 | 60.5× | 65.73% |
| Sep 2025 | 36.5× | (1.06%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| CRMD CorMedix Inc compare | 1.0× |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| DBVT DBV Technologies S.A. | 124× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)